Figure 3. KLF5 is highly associated with pancreatic cancer patient prognosis. (A) Patients in the training group with high expression of KLF5 have shorter survival times than patients with low KLF5 expression. (B) Patients in the test group with high expression of KLF5 have shorter survival times than patients with KLF5 low expression. (C) Among all 177 patients included, those with high KLF5 expression have shorter survival times than those with low KLF5 expression. (D) Patients exhibiting high KLF5 expression have shorter tumor-free survival than those exhibiting low expression of KLF5.